Drug-induced renal failure: Update on new medications and unique mechanisms of nephrotoxicity

被引:151
作者
Perazella, MA [1 ]
机构
[1] Yale Univ, Sch Med, Dept Med, Nephrol Sect, New Haven, CT 06520 USA
关键词
nephrotoxicity; renal failure; drugs; medications; crystal nephropathy; osmotic nephrosis;
D O I
10.1097/00000441-200306000-00006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Medications cause renal failure through a variety of mechanisms. Hemodynamic renal failure may result from drugs that reduce renal prostaglandins and hence renal blood flow and glomerular filtration rate. A relatively new group of drugs with this potential is the cyclooxygenase-2 selective inhibitors. Direct renal tubular toxicity has also been described with a number of new medications with unique effects on the epithelial cells of the kidney. These include the antiviral agents cidofovir, adefovir, and tenofovir as well as the bisphosphonate pamidronate. Additionally, crystal deposition in the kidney may promote the development of renal failure. Several different drugs have been described to induce crystal nephropathy, including the antiparasitic drug sulfadiazine, the antiviral agent acyclovir, and the protease inhibitor indinavir. Finally, an unusual form of renal failure characterized by swollen, vacuolated proximal tubular cells can develop from hyperosomlar substances. Agents recently described to induce an "osmotic nephrosis" include intravenous immunoglobulin and the plasma expander hydroxyethyl starch.
引用
收藏
页码:349 / 362
页数:14
相关论文
共 135 条
[1]   Intrarenal expression and distribution of cyclooxygenase isoforms in rats with experimental heart failure [J].
Abassi, Z ;
Brodsky, S ;
Gealekman, O ;
Rubinstein, I ;
Hoffman, A ;
Winaver, J .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2001, 280 (01) :F43-F53
[2]   INTRAVENOUS IMMUNOGLOBULIN - INDUCED OSMOTIC NEPHROSIS [J].
AHSAN, N ;
PALMER, BF ;
WHEELER, D ;
GREENLEE, RG ;
TOTO, RD .
ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (17) :1985-1987
[3]   Safety and efficacy of bisphosphonates beyond 24 months in cancer patients [J].
Ali, SM ;
Esteva, FJ ;
Hortobagyi, G ;
Harvey, H ;
Seaman, J ;
Knight, R ;
Costa, L ;
Lipton, A .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) :3434-3437
[4]  
Anderson WAD, 1940, J AMER MED ASSOC, V114, P1983
[5]  
[Anonymous], 1997, Ann Intern Med, V126, P264
[6]  
Arunabh, 1996, AM FAM PHYSICIAN, V53, P862
[7]  
Bach MC, 1997, J ACQ IMMUN DEF SYND, V14, P296
[8]   Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults [J].
Barditch-Crovo, P ;
Deeks, SG ;
Collier, A ;
Safrin, S ;
Coakley, DF ;
Miller, M ;
Kearney, BP ;
Coleman, RL ;
Lamy, PD ;
Kahn, JO ;
McGowan, I ;
Lietman, PS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2733-2739
[9]   ACUTE CRYOGLOBULINEMIC RENAL-FAILURE AFTER INTRAVENOUS-INFUSION OF GAMMA-GLOBULIN [J].
BARTON, JC ;
HERRERA, GA ;
GALLA, JH ;
BERTOLI, LF ;
WORK, J ;
KOOPMAN, WJ .
AMERICAN JOURNAL OF MEDICINE, 1987, 82 (03) :624-629
[10]   ADVERSE-EFFECTS OF HIGH-DOSE INTRAVENOUS ACYCLOVIR IN AMBULATORY PATIENTS WITH ACUTE HERPES-ZOSTER [J].
BEAN, B ;
AEPPLI, D .
JOURNAL OF INFECTIOUS DISEASES, 1985, 151 (02) :362-365